LX-102

LX102注射液

Report date: 2026/03/31 20:00:21

Base Information

Drug NameLX-102
Drug Alias NameLX 102 C 01LX-102-C-01LX-102LX102LX102-C01
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionVascular endothelial growth factor inhibitors
TargetsVascular endothelial growth factor
Therapy Area/IndicationsWet age-related macular degenerationMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesInnostellar Biotherapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesInnostellar Biotherapeutics Co LtdLangxin Qisheng (Suzhou) Biopharmaceutical Co Ltd +[3] 
Inactive CompaniesN/A
Active IndicationsWet age-related macular degenerationMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A